Tags

Type your tag names separated by a space and hit enter

Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations.
Arch Intern Med. 1994 May 23; 154(10):1106-10.AI

Abstract

BACKGROUND

Women who receive postmenopausal estrogen replacement experience a lower rate of coronary heart disease than women who do not receive these hormones. Evidence suggests that mechanisms in addition to decreases in plasma low-density lipoprotein levels and increases in high-density lipoprotein concentrations are responsible for the apparent beneficial effect of estrogens. Therefore, we studied the effect of estrogen on plasma Lp(a) lipoprotein, newly suggested to be a risk factor for coronary heart disease in postmenopausal women.

METHODS

The 31 healthy, normolipidemic subjects received placebo and conjugated equine estrogens (0.625 and 1.25 mg/d) for 3-month periods in a randomized, double-blind, crossover trial.

RESULTS

The mean Lp(a) lipoprotein concentration was 20.4 +/- 14.6 mg/dL during placebo treatment; it decreased by 14% (P < .01) with 0.625 mg of conjugated estrogens and by 16% (P < .005) with 1.25 mg. The Lp(a) lipoprotein concentration during placebo treatment was not significantly correlated with the responses to either dose of estrogen. There was no effect of estrogen on the plasma concentration of cholesterol ester transfer protein, suggesting that this protein is not involved in estrogen-induced changes in very-low-density lipoprotein or high-density lipoprotein concentrations and composition.

CONCLUSIONS

Estrogen decreases the plasma Lp(a) lipoprotein concentration, which could explain some of the protective effect of estrogen replacement therapy on coronary heart disease.

Authors+Show Affiliations

Department of Medicine, Brigham and Women's Hospital, Boston, Mass.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

8185424

Citation

Sacks, F M., et al. "Effect of Postmenopausal Estrogen Replacement On Plasma Lp(a) Lipoprotein Concentrations." Archives of Internal Medicine, vol. 154, no. 10, 1994, pp. 1106-10.
Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med. 1994;154(10):1106-10.
Sacks, F. M., McPherson, R., & Walsh, B. W. (1994). Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Archives of Internal Medicine, 154(10), 1106-10.
Sacks FM, McPherson R, Walsh BW. Effect of Postmenopausal Estrogen Replacement On Plasma Lp(a) Lipoprotein Concentrations. Arch Intern Med. 1994 May 23;154(10):1106-10. PubMed PMID: 8185424.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. AU - Sacks,F M, AU - McPherson,R, AU - Walsh,B W, PY - 1994/5/23/pubmed PY - 1994/5/23/medline PY - 1994/5/23/entrez SP - 1106 EP - 10 JF - Archives of internal medicine JO - Arch Intern Med VL - 154 IS - 10 N2 - BACKGROUND: Women who receive postmenopausal estrogen replacement experience a lower rate of coronary heart disease than women who do not receive these hormones. Evidence suggests that mechanisms in addition to decreases in plasma low-density lipoprotein levels and increases in high-density lipoprotein concentrations are responsible for the apparent beneficial effect of estrogens. Therefore, we studied the effect of estrogen on plasma Lp(a) lipoprotein, newly suggested to be a risk factor for coronary heart disease in postmenopausal women. METHODS: The 31 healthy, normolipidemic subjects received placebo and conjugated equine estrogens (0.625 and 1.25 mg/d) for 3-month periods in a randomized, double-blind, crossover trial. RESULTS: The mean Lp(a) lipoprotein concentration was 20.4 +/- 14.6 mg/dL during placebo treatment; it decreased by 14% (P < .01) with 0.625 mg of conjugated estrogens and by 16% (P < .005) with 1.25 mg. The Lp(a) lipoprotein concentration during placebo treatment was not significantly correlated with the responses to either dose of estrogen. There was no effect of estrogen on the plasma concentration of cholesterol ester transfer protein, suggesting that this protein is not involved in estrogen-induced changes in very-low-density lipoprotein or high-density lipoprotein concentrations and composition. CONCLUSIONS: Estrogen decreases the plasma Lp(a) lipoprotein concentration, which could explain some of the protective effect of estrogen replacement therapy on coronary heart disease. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/8185424/Effect_of_postmenopausal_estrogen_replacement_on_plasma_Lp_a__lipoprotein_concentrations_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/vol/154/pg/1106 DB - PRIME DP - Unbound Medicine ER -